The risk of ischemic stroke/thromboembolic events after an intracranial hemorrhage (ICH) in patients with atrial fi brillation (AF) who are on warfarin treatment is poorly characterized. Th e aim of this study was to assess the association between the risk of ischemic stroke/thromboembolic events and ICH.
Patients with atrial fi brillation (AF) have an increased risk for ischemic stroke, and stroke-prophylactic treatment with oral anticoagulants (OACs) is recommended if one stroke risk factor is present. 1 Treatment with antithrombotic agents such as the vitamin K antagonists (VKAs) (eg, warfarin) reduces stroke by 64% and all-cause mortality by 26%, when compared with placebo or a control. 2 However, patients on warfarin therapy are also at a higher risk of bleeding, the most severe being spontaneous intracranial hemorrhage (ICH). Indeed, anticoagulationassociated intracerebral hemorrhage has been reported to account for 20% of all ICH events. 3 Th e anxiety of causing serious bleeding (particularly ICH) can lead physicians to withhold anticoagulants in some patients with AF, despite a greater benefi t from OAC treatment (compared with no OAC or aspirin treatment) in terms of reduced risk of stroke. [4] [5] [6] More recently, the non-VKA OACs (NOACs, previously referred to as new or novel OACs 7 ) have been shown to be associated with lower rates of ICH compared with VKAs, improving safety, in addition to their effi cacy and convenience. [8] [9] [10] Nonetheless, a history of ICH was an exclusion criterion for patients included in recent trials of NOACs compared with VKAs.
In clinical practice, an ICH event necessitates temporary cessation of OAC therapy, requiring the physician to balance the risk of an additional bleeding event with the risk of a thromboembolic event in the absence of OAC treatment. 11 Th e preferred timing of OAC therapy resumption aft er an ICH event has been much debated, 12, 13 and suggestions diff er from 7 to 14 days to 30 weeks. [14] [15] [16] In practice, however, the timing of OAC therapy resumption is diffi cult, and attempts to err on the side of caution may lead to general undertreatment (or nontreatment), resulting in an increased risk for further fatal and disabling stroke among survivors of ICH.
Th e objective of this study was to investigate outcomes of ischemic stroke and thromboembolic events associated with ICH among patients with AF. We hypothesized that patients experiencing an ICH event would be at increased risk for thromboembolism, as refl ected by a composite of ischemic stroke, systemic embolism, and transient ischemic attack (TIA), and by all-cause mortality. Further, we hypothesized that this increase in risk for thromboembolism among survivors of ICH would be accompanied by a decreased rate of warfarinprescription purchase. We investigated these hypotheses in a large, nationwide cohort study.
Materials and Methods

Registry Data Sources and Study Population
All Danish residents are given a unique and permanent registration number at the time of birth or immigration. Nationwide registries enable retrieval of individual patient data on (1) discharge diagnosis classifi ed by the International Classifi cation of Diseases, 10th Revision (ICD-10) and admission and discharge dates (the Danish National Patient Registry); (2) dispensed prescriptions identified by the Anatomic Therapeutic Chemical classification code, date of purchase, package size and volume of the medication since 1994 (the Danish National Prescription Registry); and (3) information on sex, date of birth, emigration, and vital status (the Danish Civil Registration System).
By linking the three databases, [17] [18] [19] we established a cohort of patients with incident nonvalvular AF. Nonvalvular AF was defi ned as presence of ICD-10 diagnosis code I48, and baseline absence of mitral stenosis and mechanical heart valve (ICD-10 diagnosis codes: I05 and Z952-Z954). Specifi cally, we identifi ed all patients discharged with a fi rst-time hospital diagnosis (index date) of nonvalvular AF in the period January 1, 1999, to December 31, 2012. e-Appendix 1 gives detailed defi nitions on outcomes and concomitant pharmacotherapy. We excluded patients who died or experienced an ICH event (ICD-10 diagnosis codes: I60-I62, S063C, S064-S066, I690-I692) within the fi rst 7 days aft er the index date. Patients who had claimed a prescription of heparin or low-molecular-weight heparin or non-VKAs 1 year prior to the index date were also excluded. We further restricted the cohort to patients who initiated warfarin treatment, defi ned as a warfarin prescription claim within the fi rst 30 days aft er the index date.
Outcome Measures and Comorbidity
Patients were followed in the National Patient Registry from the index date (baseline) until the occurrence of the studied end point, emigration, end of study, or death, whichever came first. The primary end point was the composite of ischemic stroke/systemic embolism/TIA (ICD-10 diagnosis codes I63, I64, I74, G45). Secondary analyses were done on major bleeding, as well as all-cause mortality. Th e defi nition of major bleeding included acute posthemorrhagic anemia, hemothorax, conjunctival hemorrhage, retinal hemorrhage, vitreous hemorrhage, recurrent and persistent hematuria, menopausal and other perimenopausal disorders, hemorrhage from the respiratory passages, unspecified hematuria, and unclassifi ed hemorrhage (ICD-10 diagnosis codes D62, J942, H113, H356, H431, N02, N95, R04, R31, R58). 20 We imposed a dynamic stratifi cation on the cohort by considering each patient's ICH status during follow-up. At the index date, all patients were ICH free. If a patient sustained an ICH, they would move irreversibly to the ICH group. Survivors of ICH were defi ned on the basis of the vital status from the Danish Civil Registration System (ie, no change in the vital status at the day of an ICH diagnosis).
The cardiovascular comorbidity and risk for stroke at baseline were assessed by the CHA 2 DS 2 -VASc (cardiac failure or dysfunction, hypertension, age Ն 75 years [doubled], diabetes, stroke [doubled]-vascular disease, age 65-74 years, and sex category [female]) score, with higher scores indicating greater risk for stroke. 21 Th e CHA 2 DS 2 -VASc score has previously been applied in similar nationwide cohorts and is the preferred risk stratifi cation tool for patients with AF, as recommended by the European Society of Cardiology. [22] [23] [24] [25] We also calculated a (modifi ed) HAS-BLED score (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly [ . 65 years], drugs [antiplatelet drugs or nonsteroidal antiinfl ammatory drugs]/alcohol excess concomitantly), but excluding labile international normalized ratio (INR) due to lack of data, for each patient to assess the risk of bleeding. Higher scores indicate greater risk of bleeding events. 23 Concomitant pharmacotherapy at baseline was defi ned as a prescription claim within 1 year prior to the index date.
Statistical Analysis
We performed three separate analyses. First, we compared the rate of stroke/systemic embolism/TIA, major bleeding, and all-cause mortality in the ICH group relative to the ICH-free group, defi ned according to the dynamic stratifi cation. Second, we applied a case-crossover analysis among ischemic stroke/systemic embolism/TIA cases to describe the association between an ICH event and risk for ischemic stroke/systemic embolism/TIA. Third, we assessed among ICH survivors the rate of warfarin prescription purchases in a period before and aft er the ICH event.
Crude event rates of stroke/systemic embolism/TIA were calculated as the number of events divided by the total person-time within each of the dynamic ICH strata, and rates were compared using the MantelHaenzel rate-ratio method. Th is was done for 2 years of follow-up and using the entire follow-up period. Cumulative risk of stroke/systemic embolism/TIA as a function of time since ICH (taking into account competing risk for death 26 ) was calculated to describe the absolute risk of stroke/systemic embolism/TIA in survivors of ICH. Events occurring within 7 days of the ICH event were excluded. To further investigate the outcomes for patients who sustained an ICH event, we performed a substudy to evaluate the presence of risk factors for ischemic stroke. Th is was done by using the Cox proportional hazards model to compare rates of stroke/systemic embolism/TIA in survivors of ICH on relative levels of (baseline) parameters in the CHA 2 DS 2 -VASc score. Th ese analyses were adjusted for sex (binary), age (continuous), and year of inclusion (categorical); age adjustment was not applied when analyzing age 65 to 74 years and age Ն 75 years.
We applied a case-crossover design to investigate the association between ICH and short-term risk for subsequent ischemic stroke/systemic embolism/TIA. Th e case-crossover is a case-only design that allows a patient to function as his or her own control subject by considering events in two separate time periods relative to the outcome of interest. 27, 28 Th is self-controlled design controls for confounding by covariates that are (approximately) constant over the study period. We selected all incident cases of stroke/systemic embolism/TIA and ascertained occurrence of ICH in case periods and control periods, defi ned as 3 months prior to stroke/systemic embolism/TIA (case) and 6 to 3 months prior to stroke/systemic embolism/TIA (control period). A matched OR to assess the relative odds of an ICH event according to period was calculated using the McNemar test for matched pair's data. A sensitivity analysis assessing the defi nitions of the case and control periods was conducted by extending and reducing, respectively, the periods by 1 and 2 months. Further, a sensitivity analysis to assess the potential impact of seasonal variation was conducted by moving the control period to 9 to 6 months prior to the stroke/systemic embolism/TIA event.
Changes in exposure to warfarin following an ICH event were investigated by calculating the ratio of rates of warfarin purchase in a 3-month period immediately aft er and immediately before an event of ICH. Th e rates were calculated as the number of warfarin purchases divided by the person-time in the two 3-month periods.
A two-sided P value , .05 was considered statistically signifi cant. SAS 9.3 (SAS Institute Inc) and Stata/MP 13 (StataCorp LP) were used for the statistical analyses.
Results
A fl owchart of the study is provided in Figure 1 . In a cohort of 212,332 patients with incident nonvalvular AF, ascertained from January 1, 1999, to December 31, 2012, we identifi ed 58,815 patients who satisfi ed the inclusion criteria. Of these patients, 1,639 (2.8%) had an incident ICH event, and 6,994 (11.9%) had a stroke/systemic embolism/TIA event, where the majority of this combined outcome was attributed to ischemic stroke (76.1%). The 30-day mortality rate of ICH was 44.2%. Median age of the study population was 72.6 years (interquartile range, 64.6-79.3 years), 60.0% were men, and 68.9% had a baseline CHA 2 DS 2 -VASc score Ն 2 ( Table 1 ) .
Stroke/Systemic Embolism/TIA Relative to ICH
Th e rates of stroke/systemic embolism/TIA per 100 person-years based on the full follow-up period in the ICH and non-ICH groups were 9.59 and 2.62, respectively. Th is led to an increased rate ratio of 3.67 (95% CI, 3.12-4.31) (vs reference non-ICH) ( Table 2 ) . Excluding TIA events from the composite outcome did not alter the conclusion. Th e rate ratio for all-cause mortality was 5.55 (95% CI, 5.20-5.92), and for major bleeding events, 1.06 (95% CI, 0.81-1.39). Th e increased rate of stroke/systemic embolism/TIA and all-cause mortality, compared with patients without ICH, was more pronounced for 2 years of follow-up ( Table 3 ) .
Th e absolute risk of stroke/systemic embolism/TIA among survivors of ICH was markedly increased during the fi rst 90 days aft er an ICH event ( Fig 2 ) . Hazard ratios for subsequent ischemic stroke/systemic embolism/TIA events in patients sustaining an ICH event were similar irrespective of selected baseline risk factors (based on the CHA 2 DS 2 -VASc score) at 2 years of follow-up ( Fig 3 ) .
A matched OR for occurrence of a recent ICH was calculated for all patients who had an event of stroke/systemic embolism/TIA, to investigate the short-term risk of subsequent stroke/systemic embolism/TIA in patients who sustained an ICH event ( Fig 4 ) . Of 6,994 patients, 5,169 had suffi cient history ( . 6 months) to be included. Within this subgroup, 146 patients were identifi ed as cases, which means they had an ICH event prior to an event of stroke/systemic embolism/TIA; 80 ICH events occurred within 6 months prior to the stroke/systemic embolism/TIA. During the case period (ie, 3 months prior to the stroke/systemic embolism/TIA), 65 patients had an ICH, while during the control period, 15 patients had an ICH.
Th e matched OR of having an ICH in the case vs the control period was 4.33 (95% CI, 2.44-8.18), which highlights the association of an increased risk for stroke/systemic embolism/TIA aft er an ICH event. A sensitivity analysis of prolonging and restricting the case and control periods did not qualitatively alter the results ( Fig 4 ) . Moving the control period relative to the case period to investigate the potential impact of seasonal variation reduced the number of subjects in the analysis but did not change the OR substantially (data not shown). A sensitivity analysis confi ning the end point of interest to "ischemic stroke" only or "ischemic Table 1 legend for expansion of other abbreviation. stroke/systemic embolism" did not change our conclusions materially (data not shown).
Warfarin Treatment Relative to ICH
Th e subcohort of survivors of ICH was analyzed to assess exposure to warfarin treatment before and aft er an ICH event. Th e rate of claimed warfarin prescriptions was strongly and signifi cantly reduced in 3 months aft er an ICH event compared with 3 months before (rate ratio, 0.28; 95% CI, 0.24-0.33). Similar eff ect size estimates were seen when restricting (rate ratio, 0.33; 95% CI, 0.29-0.38) or extending (rate ratio, 0.24; 95% CI 0.20-0.39) the periods by 1 month.
Discussion
Our principal fi ndings were an increased rate of ischemic stroke and all-cause mortality in patients with AF who survived an ICH event compared with patients who had not experienced an ICH event. Second, among survivors of ICH, we observed a decrease in the warfarinprescription purchase rate in the post-ICH period compared with pre-ICH period.
Th is register-based cohort study was undertaken to investigate the association between ICH and subsequent ischemic thrombotic events in patients with nonvalvular AF receiving warfarin treatment. Th e lack of controlled clinical trials assessing whether to reverse OACs and when to resume thromboprophylactic treatments poses a dilemma for clinicians: Having survived the acute phase, how does the increased risk for stroke/systemic embolism/TIA compare with the risk for recurrent ICH if OAC therapy is not restarted? Our study suggests that the risk for stroke/systemic embolism/TIA is, indeed, substantially increased, being up to a fi vefold increase within the fi rst 3 months aft er an ICH event.
In the Swedish AF cohort study, Friberg et al 29 found that previous ICH was an independent predictor for subsequent ischemic stroke, reporting an adjusted hazard ratio of 1.49.
Our fi ndings show a decreased rate of claims of warfarin prescriptions post-ICH, where the rate ratio of warfarin prescriptions was 0.33, which could indicate that only one-third of the patients restarted OAC treatment within the same time frame (3 months ). A recent analysis by Qureshi et al 30 found that outcomes from thromboembolism were worse where OACs were discontinued following GI hemorrhage. In contrast, a decision to restart OAC therapy aft er an episode of major GI bleeding was associated with improved survival and decreased systemic embolism without increased risk of major GI bleeding recurrence aft er 7 days of interruption. It is important, however, to emphasize that the present analysis cannot be used to infer that the association between ICH and ischemic stroke is (causally) mediated by warfarin treatment. On the other hand, due to the lower risk of ICH among patients treated with the NOACs compared with warfarin, 10 it might be reasonable to consider these drugs instead of VKAs when considering a resumption of OACs. However, well-designed, clinically controlled trials investigating the optimal drug selection post-ICH are needed. Importantly, further investigation is needed to identify the cut of point in time when to restart warfarin. Indeed, one feasible approach could be done by using prospective registries of patients who sustain an ICH event.
Study Limitations
Th is observational study might be subject to ascertainment bias (ie, only hospital-diagnosed patients with AF are studied), and incompletely ascertained variables could lead to biased measures of associations. Also, the population registries lacked various important variables, which might have further elucidated associations. We did not have access to INR data, which are closely related to thromboembolic events as well as ICH events. 9, 31 The ICH defi nition based on the registry data does not allow for analysis of the location and type of ICH, which could aff ect the outcome in survivors of ICH. 32 Indeed, patients with lobar hemorrhage or cerebral amyloid angiopathy remain at higher risk for further anticoagulant-related ICH recurrence than thromboembolic events, and current consensus suggests that such patients should be best managed without OACs. 14 In contrast, patients with deep hemispheric ICH and a baseline risk for ischemic stroke (eg, CHA 2 DS 2 -VASc score Ն 5), may receive net benefi t from restarting OAC therapy, especially if risk factors such as uncontrolled BP, labile INRs (as refl ected by time in therapeutic range), and concomitant aspirin/nonsteroidal antiinfl ammatory drug use in an anticoagulated patient are addressed. 14 Our lack of cerebral imaging data does not allow an assessment of ICH volume (which may be higher in warfarin users 33 ), and is predictive of adverse outcomes. 34, 35 In conclusion, this nationwide cohort study clearly showed that an incident event of ICH was associated with a subsequent increased risk for ischemic stroke/ systemic embolism/TIA and mortality but not major bleeding when compared with patients without ICH. Th is association may possibly be due to cessation of warfarin prescription in patients with AF, who are predisposed to an increased risk for stroke and thromboembolism.
